Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab with High-Dose Chemotherapy and ASCT for CNS Lymphoma
NCT01182415Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Jun 2010
- Primary completion
- Dec 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in central nervous system lymphoma, non-Hodgkin lymphoma (NHL), sponsored by Massachusetts General Hospital. Started Jun 2010; status: completed.
02
Drugs
rituximab
03
Conditions
central nervous system lymphomanon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT01182415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01182415.